TherapeuticsMD Inc. (TXMD)’s Financial Results Comparing With Eli Lilly and Company (NYSE:LLY)

Both TherapeuticsMD Inc. (NASDAQ:TXMD) and Eli Lilly and Company (NYSE:LLY) are Drug Manufacturers – Major companies, competing one another. We will contrast their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
TherapeuticsMD Inc. 15.13M 88.81 114.65M -0.52 0.00
Eli Lilly and Company 24.56B 5.03 3.23B 2.27 50.17

Table 1 highlights TherapeuticsMD Inc. and Eli Lilly and Company’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 shows us TherapeuticsMD Inc. and Eli Lilly and Company’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
TherapeuticsMD Inc. -757.77% -102.1% -68%
Eli Lilly and Company 13.15% 3.5% 1%

Volatility and Risk

TherapeuticsMD Inc. is 36.00% more volatile than S&P 500 because the stock has a beta of 1.36. Competitively, Eli Lilly and Company’s 69.00% volatility makes it less volatile than S&P 500, because of the 0.31 beta.


The Current Ratio and a Quick Ratio of TherapeuticsMD Inc. are 7.2 and 7.1. Competitively, Eli Lilly and Company has 1.9 and 1.5 for Current and Quick Ratio. TherapeuticsMD Inc.’s better ability to pay short and long-term obligations than Eli Lilly and Company.


Eli Lilly and Company also pays out annual dividends at $2.25 per share and at a 1.86% dividend yield. No dividend is paid out by TherapeuticsMD Inc.

Analyst Recommendations

TherapeuticsMD Inc. and Eli Lilly and Company Ratings and Recommendations are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
TherapeuticsMD Inc. 0 0 0 0.00
Eli Lilly and Company 0 4 3 2.43

Eli Lilly and Company on the other hand boasts of a $115.75 average target price and a -5.49% potential downside.

Institutional & Insider Ownership

Roughly 74.2% of TherapeuticsMD Inc. shares are owned by institutional investors while 80% of Eli Lilly and Company are owned by institutional investors. About 8.5% of TherapeuticsMD Inc.’s share are owned by insiders. Competitively, insiders own roughly 11.2% of Eli Lilly and Company’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
TherapeuticsMD Inc. -13.32% -6.64% -30.24% -38.07% -28.29% -27.81%
Eli Lilly and Company -3.84% 3.98% 7.21% 32.88% 32.86% 35.08%

For the past year TherapeuticsMD Inc. has -27.81% weaker performance while Eli Lilly and Company has 35.08% stronger performance.


Eli Lilly and Company beats on 11 of the 13 factors TherapeuticsMD Inc.

TherapeuticsMD, Inc. operates as a womenÂ’s health care product company. The company manufactures and distributes prescription and over-the-counter product lines, including prenatal vitamins, iron supplements, and natural menopause relief products under the vitaMedMD brand, as well as generic formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen. The company markets its products primarily through a direct national sales force to health care providers in the OB/GYN market space. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. It operates through two segments, Human Pharmaceutical Products and Animal Health Products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia; and migraine headaches. Further, it provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry; and chewable tablets that kill fleas and prevent flea infestations, and heartworm diseases, as well as controls intestinal parasite infections. Additionally, the company offers vaccinev to prevent Lyme disease, bronchial infections, rabies, and various infectious diseases in dogs, cats, and horses. It has collaboration agreements with Daiichi Sankyo Co., Ltd., Incyte Corporation, Pfizer Inc., AstraZeneca, William Sansum Diabetes Center, Purdue University, and Nektar Therapeutics. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.


Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.